Introduction: Diabetes is a condition that impairs carbohydrate, fat, and protein metabolism in the body. At the point when we eat food, the food is separated into glucose and supplements and is invested in the blood.

Objective: The main objective of the study is to analyse the sitagliptan vs empagliflozin as an add-on therapy to metformin in Pakistani type 2 diabetic patients.

Material and methods: This comparative study was conducted with the collaboration of different hospitals of Pakistan in different regions during November 2020 to September 2021. Fasting blood sample was collected for the analysis of serum blood glucose levels and body weight, waist circumference, systolic blood pressure (SBP), and diastolic blood pressure (DBP) were also measured on daily basis.

Results: The data was collected from 200 patients. The basic demographic characteristics of all the patients were shown in table 01. There were 86 (43%) male and 114 (57%) female patients. The mean value of HbA1C was 10.07 and 112 patients suffering from hypertension and 46 from heart diseases.

Conclusion: It is concluded that empagliflozin is an effective agent in treating patients with type 2 diabetes, with good efficacy and safety profiles.